Market by Product Type, Therapeutic Application, and End-user | Forecast 2023-2028
Triton Market Research’s report estimates that
the market for botulinum toxin type A in Australia would witness a CAGR of 10.80% by revenue over the forecast
period 2023-2028. It is expected to
attain $XX million by 2028.
The pure version of botulinum toxin, known as
miracle poison or botulinum toxin type A, is used to prevent the release of
acetylcholine in treating dystonia, persistent sialorrhea, and muscle
stiffness. Moreover, it is used to treat incontinence in adult patients who are
not candidates for anticholinergic therapy, adults with symptomatic overactive
bladder with or without incontinence, and patients over 5 who cannot undergo
anticholinergic therapy.
Additionally, it is used off-label for several
conditions, including neurogenic thoracic outlet syndrome, myofascial pain,
post-herpetic neuralgia, epicondylitis, post-stroke pain, trigeminal neuralgia,
diabetic neuropathy, neuropathic pain, spinal cord injury, and bladder pain.
The most popular preparation, botulinum toxin
type A, is available in commercially viable versions in Australia: Botox®
(Allergan Pharmaceuticals), Xeomin® (Merz Pharmaceuticals), and Dysport® (Ipsen
Pharmaceuticals). Botulinum toxin is a scheduled drug subject to approval and
regulation by the Therapeutic Goods Administration.
Because there is less recovery time following
treatment, non-invasive therapies such as Botox are becoming increasingly
popular in the country. Minimally invasive therapies have advantages over
invasive treatments, including smaller incisions, shorter hospital stays,
quicker outpatient services, quicker wound healing, less discomfort, and a
lower risk of complications. As a result, the demand for botulinum toxin is anticipated to increase throughout the anticipated period.
Triton Market Research’s report provides
in-depth insight into the Australia botulinum toxin type A market, along with
segmentation analysis. The detailed analysis of the market includes PEST
analysis, current market trends, regulatory framework, and insurance system &
reimbursements. The segmentation analysis
includes market by product type, therapeutic application, and end-user.
The
key players in the botulinum toxin type A market are Abbvie Inc, Hugel Inc,
Merz Pharma, Medytox Inc, and Ipsen Pharma.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. AUSTRALIA
BOTULINUM TOXIN TYPE A MARKET – SUMMARY
1.1. MARKET
SIZE & FORECAST
1.2. COUNTRY
ANALYSIS
1.3. MARKET
DRIVING ASPECTS
1.3.1. PENETRATION
OF NON-INVASIVE THERAPEUTIC PROCEDURES
1.3.2. GROWING
PREVALENCE OF MIGRAINE
1.4. MARKET
RESTRAINING ASPECT
1.4.1. EASY
AVAILABILITY OF OTC DRUGS FOR MIGRAINES
2. AUSTRALIA
BOTULINUM TOXIN TYPE A MARKET OUTLOOK
2.1. PEST
ANALYSIS
2.2. CURRENT
MARKET TRENDS
2.3. KEY
MARKET STRATEGIES
2.3.1. COLLABORATIONS
2.3.2. PRODUCT
LAUNCHES AND DEVELOPMENTS
2.3.3. ACQUISITIONS
2.4. POTENTIAL
FOR NEW ENTRANTS IN AUSTRALIA BOTULINUM TYPE A MARKET
2.5. MARKET
ATTRACTIVENESS INDEX
2.6. REGULATORY
FRAMEWORK
2.7. INSURANCE
SYSTEM AND REIMBURSEMENTS
2.7.1. HEALTHCARE
& INSURANCE SYSTEM
2.7.2. REIMBURSEMENT
FOR THERAPEUTIC BOTOX TREATMENT
3. AUSTRALIA
BOTULINUM TOXIN TYPE A MARKET OUTLOOK - BY PRODUCT TYPE
3.1. ABOBOTULINUMTOXIN
TYPE A
3.2. INCOBOTULINUMTOXIN
TYPE A
3.3. ONABOTULINUMTOXIN
TYPE A
4. AUSTRALIA
BOTULINUM TOXIN TYPE A MARKET OUTLOOK - BY THERAPEUTIC APPLICATION
4.1. CHRONIC
MIGRAINE
4.2. SPASTIC
DISORDERS
4.3. CERVICAL
DYSTONIA
4.4. DETRUSOR
OVERACTIVITY
4.5. OTHER
THERAPEUTIC APPLICATIONS
5. AUSTRALIA
BOTULINUM TOXIN TYPE A MARKET OUTLOOK - BY END-USER
5.1. HOSPITALS
AND CLINICS
5.2. OTHER
END-USERS
6. COMPETITIVE
LANDSCAPE
6.1. ABBVIE
INC
6.2. HUGEL
INC
6.3. IPSEN
PHARMA
6.4. MERZ
PHARMA
6.5. MEDYTOX
INC
7. RESEARCH
METHODOLOGY & SCOPE
7.1. RESEARCH
SCOPE & DELIVERABLES
7.2. SOURCES
OF DATA
7.3. RESEARCH
METHODOLOGY
TABLE 1: THERAPEUTIC
APPLICATIONS FOR BOTULINUM TOXIN
TABLE 2: REGULATORY FRAMEWORK
FOR AUSTRALIA BOTULINUM TOXIN TYPE A MARKET
TABLE 3: AUSTRALIA BOTULINUM
TOXIN TYPE A MARKET, BY PRODUCT TYPE, 2023-2028 (IN $ MILLION)
TABLE 4: AUSTRALIA BOTULINUM
TOXIN TYPE A MARKET, BY THERAPEUTIC APPLICATION, 2023-2028 (IN $ MILLION)
TABLE 5: AUSTRALIA BOTULINUM
TOXIN TYPE A MARKET, BY END-USER, 2023-2028 (IN $ MILLION)
TABLE 6: LIST OF BOTULINUM
TOXIN TYPE A MARKET COLLABORATIONS
TABLE 7: LIST OF BOTULINUM
TOXIN TYPE A MARKET PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 8: LIST OF BOTULINUM
TOXIN TYPE A MARKET ACQUISITIONS
FIGURE
1: MARKET ATTRACTIVENESS INDEX
FIGURE
2: AUSTRALIA BOTULINUM TOXIN TYPE A MARKET, BY PRODUCT TYPE, 2022 & 2028
(IN %)
FIGURE
3: AUSTRALIA BOTULINUM TOXIN TYPE A MARKET, BY ABOBOTULINUMTOXIN TYPE A,
2023-2028 (IN $ MILLION)
FIGURE
4: AUSTRALIA BOTULINUM TOXIN TYPE A MARKET, BY INCOBOTULINUMTOXIN TYPE A,
2023-2028 (IN $ MILLION)
FIGURE
5: AUSTRALIA BOTULINUM TOXIN TYPE A MARKET, BY ONABOTULINUMTOXIN TYPE A,
2023-2028 (IN $ MILLION)
FIGURE
6: AUSTRALIA BOTULINUM TOXIN TYPE A MARKET, BY THERAPEUTIC APPLICATION, 2022
& 2030 (IN %)
FIGURE
7: AUSTRALIA BOTULINUM TOXIN TYPE A MARKET, BY CHRONIC MIGRAINE, 2023-2028 (IN
$ MILLION)
FIGURE
8: AUSTRALIA BOTULINUM TOXIN TYPE A MARKET, BY SPASTIC DISORDERS, 2023-2028 (IN
$ MILLION)
FIGURE
9: AUSTRALIA BOTULINUM TOXIN TYPE A MARKET, BY CERVICAL DYSTONIA, 2023-2028 (IN
$ MILLION)
FIGURE
10: AUSTRALIA BOTULINUM TOXIN TYPE A MARKET, BY DETRUSOR OVERACTIVITY,
2023-2028 (IN $ MILLION)
FIGURE
11: AUSTRALIA BOTULINUM TOXIN TYPE A MARKET, BY OTHER THERAPEUTIC APPLICATIONS,
2023-2028 (IN $ MILLION)
FIGURE
12: AUSTRALIA BOTULINUM TOXIN TYPE A MARKET, BY END-USER, 2022 & 2030 (IN
%)
FIGURE
13: AUSTRALIA BOTULINUM TOXIN TYPE A MARKET, BY HOSPITALS AND CLINICS,
2023-2028 (IN $ MILLION)
FIGURE
14: AUSTRALIA BOTULINUM TOXIN TYPE A MARKET, BY OTHER END-USERS, 2023-2028 (IN
$ MILLION)